Tonix Pharma soars 33% on Fibromyalgia drug approval hopes
Tonix Pharmaceuticals jumped 33% to $14.79, its best day since March, ahead of Friday's FDA decision on TNX-102 SL, which could become the first new fibromyalgia drug in 16 years. The late-stage therapy earned Fast Track status and showed strong Phase 3 results. Retail sentiment surged, with message volume up 222%.